Abstract
Despite continuous prevention and control strategies in place, malaria remains a major public health problem in sub-Saharan Africa including Ethiopia. This study is, therefore, aimed to determine the prevalence of plasmodium infection and associated risk factors in selected rural kebeles in southern Ethiopia. A community-based cross-sectional study was conducted between January and June 2019. Mult-stage sampling techniques were employed to select the study districts and kebeles from four zones. Blood sample were taken from 1674 participants by finger prick and thin and thick smears were examined by microscopy. Socio-demographic data as well as risk factors for malaria infection were collected using questionnaires. Bivariate and multivariate logistic regressions were used to analyze the data. The overall prevalence of malaria in the study localities was 4.5% (76/1674). The prevalence was varied among the study localities with high prevalence in Bashilo (14.6%; 33/226) followed by Mehal Korga (12.1%; 26/214). Plasmodium falciparum was the dominant parasite accounted for 65.8% (50/76), while P. vivax accounted 18.4% (14/76). Co-infection of P. falciparum and P. vivax was 15.8% (12/76). The prevalence of malaria was 7.8% (27/346) in age less than 5 years and 7.5% (40/531) in 5-14 years. The age groups >14years were less likely infected with plasmodium parasite (AOR=0.14, 95% CI 0.02-0.82). Asymptomatic individuals more likely had malaria infection (AOR = 28.4, 95% CI 011.4-70.6). Individuals living proximity to mosquito breeding sites have higher malaria infection (AOR = 6.17, 95% CI 2.66 - 14.3). Malaria remains a public health problem in the study localities with lower age group and asymptomatic individuals had higher plasmodium infection. Thus, malaria prevention and control strategies targeting children and asymptomatic cases are crucial to reduce malaria related morbidity and mortality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed and approved by the Ethical Review Committee of Arba Minch University (Ref.No.CMHS/12033592/111).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email address Girma Yutura, GY: girmayutura{at}gmail.com, Fekadu Massebo, FM: fekadu.massebo{at}amu.edu.et, Nigatu Eligo, NE: nigatu.eligo{at}amu.edu.et, Abena Kochora, AK: abenakochora{at}gmail.com, Teklu Wegayehu, TW: tekluweg2007{at}yahoo.com
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
